Don't Sell Amarin Short

The following video is part of our "Motley Fool Conversations" series, in which health care editor/analyst David Williamson discusses topics from across the investing world.

This video takes a closer look at Amarin, which has been on a tear lately, up 40% over the last 3 months. While some may think this run is overblown, Amarin has a lot going for it. David highlights three important drivers for the company and why Wall Street is right in predicting big things for the small company.

Health care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health care company that he believes is poised for monster returns. To uncover this top pick today, enjoy our special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

At the time thisarticle was published David Williamsonowns shares of Amarin. The Motley Fool owns shares of GlaxoSmithKline.Motley Fool newsletter services recommendGlaxoSmithKline and Teva Pharmaceutical Industries. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.